Columbia Undergraduate Science Journal In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 and Healing Peptides: Hype or Hope? A Doctor's Comprehensive Perspective MSK Doctor Zaid Matti FDA Finds Sterility Lapses at Compounding Facilities The Partnership for Safe Medicines posted on the topic LinkedIn Peptide BPC 157 Does It Work? Breaking Down the Evidence and the Hype